Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marcus Borenäs
Observed name:
Borenäs, Marcus
Institution:
University of Gothenburg
Observed institution:
University of Gothenburg
ORCID:
0009-0007-6326-5224
Observed ORCID:
0009-0007-6326-5224
OpenAlex ID:
A5017973457
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
2021
·
Marcus Borenäs
, Ganesh Umapathy
, et al.
·
The EMBO Journal
·
62
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
2019
·
Muhammad Wasi Alam
, Marcus Borenäs
, et al.
·
Frontiers in Oncology
·
44
PDF
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
2019
·
Diana Cervantes-Madrid
, Joanna Szydzik
, et al.
·
Scientific Reports
·
30
PDF
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
2023
·
Marcus Borenäs
, Ganesh Umapathy
, et al.
·
Proceedings of the National Academy of Sciences
·
29
PDF
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements
2019
·
Niloufar Javanmardi
, Susanne Fransson
, et al.
·
Genes Chromosomes and Cancer
·
29
IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway
2023
·
Jikui Guan
, Marcus Borenäs
, et al.
·
Cancers
·
23
PDF
Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth
2024
·
Wei-Yun Lai
, Tzu-Po Chuang
, et al.
·
Cell Death and Differentiation
·
16
Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactions
2025
·
Joachim T Siaw
, Peter Merseburger
, et al.
·
The Journal of Pathology
·
11
ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN
2025
·
Marcus Borenäs
, Dan Lind
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
2
PDF
RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells
2026
·
Joachim Tetteh Siaw
, Arne Claeys
, et al.
·
iScience
·
1
Novel signaling and treatment regimes in Anaplastic Lymphoma Kinase driven neuroblastoma models
2024
·
Borenäs, Marcus
·
Gothenburg University Publications Electronic Archive (Gothenburg University)
·
1
FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma
2024
·
Perla Pucci
, Charlotte Barrett
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
RUVBL1 and RUVBL2 as novel druggable DNA Damage Response regulators in the N-Myc regulatory network in neuroblastoma
2023
·
Jimmy Van den Eynden
, Joachim Siaw
, et al.
·
Research Square
·
1
PDF
Abstract 3544: ALK signaling activity stabilizes SLC3A2 protein levels in neuroblastoma tumorigenesis
2023
·
Wei-Yun Lai
, Tzu-Po Chuang
, et al.
·
Cancer Research
·
1
Abstract B002: ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
2024
·
Ruth H. Palmer
, Bengt Hallberg
, et al.
·
Cancer Research
Abstract C159: ALK signaling primes the DNA damage response allowing exploitation of ATR inhibition in ALK-driven Neuroblastoma
2023
·
Marcus Borenäs
, Ganesh Umapathy
, et al.
·
Molecular Cancer Therapeutics
RUVBL1 and RUVBL2 as Novel Druggable DNA Damage Response Regulators in the N-Myc Regulatory Network in Neuroblastoma
2023
·
Joachim Tetteh Siaw
, Arne Claeys
, et al.
·
SSRN Electronic Journal
Abstract A36: Targeting anaplastic lymphoma kinase in neuroblastoma
2020
·
Jikui Guan
, Diana Cervantes-Madrid
, et al.
·
Cancer Research
Show more works
View as search
Works count:
18
Citation count:
250
H-index:
8
I10-index:
8
Year
Topic
Type